ストックスクリーナーアプリを入手
19.89
0.10%
0.08
前日終値:
$19.81
開ける：
$19.98
24時間の取引高:
1.83M
Relative Volume:
0.86
時価総額：
$3.28B
収益：
-
当期純損益:
$-446.21M
株価収益率:
-5.6133
EPS:
-3.5434
ネットキャッシュフロー:
$-423.92M
1週間 パフォーマンス:
+7.89%
1か月 パフォーマンス:
+10.66%
6か月 パフォーマンス:
+19.96%
1年 パフォーマンス:
+152.61%
1日の値動き範囲:
$19.40
$21.43
1週間の範囲:
$18.14
$21.43
52週間の値動き範囲:
$7.38
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.85 | 3.27B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
444.65 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.40 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.42 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.36 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.84 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? - Yahoo Finance
Potential Leadership Change at FDA Could Affect Dyne Therapeutics (DYN) - GuruFocus
Portfolio Shifts: Is Dyne Therapeutics Inc being accumulated by smart money2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Breakouts Watch: Will Dyne Therapeutics Inc benefit from government policy2026 Review & Growth Focused Stock Reports - baoquankhu1.vn
Chipmakers Recap: Is Dyne Therapeutics Inc gaining market share2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Travel Stocks: Is now the right time to enter Dyne Therapeutics IncIPO Watch & Safe Capital Growth Plans - baoquankhu1.vn
Dyne Therapeutics (NASDAQ: DYN) asks shareholders to approve 400M-cap increase - Stock Titan
Fundamentals Check: Is Dyne Therapeutics Inc gaining market share2026 Dividend Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Precision Trading with Dyne Therapeutics Inc. (DYN) Risk Zones - Stock Traders Daily
Signal Recap: Is Dyne Therapeutics Inc gaining market shareGap Down & Daily Volume Surge Signals - baoquankhu1.vn
DYN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Dyne Therapeutics Inc benefit from green energy policiesMarket Activity Recap & Fast Gain Stock Tips - baoquankhu1.vn
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Bullish analyst opinion on Dyne (DYNE) follows rare disease drug progress in Japan - MSN
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
Dyne Therapeutics Inc (DYN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Posner Brian S | Director |
Mar 30 '26 |
Buy |
17.08 |
2,000 |
34,160 |
15,500 |
2.51%
0.09%
大文字化:
|
ボリューム (24 時間):